BioNTech's Cancer Ambitions Meet a Shrinking Covid Franchise

BioNTech closed at EUR 83.80, down 2.6%, as shrinking Comirnaty sales and a BMO downgrade offset promising Gotistobart cancer data.

BioNTech closed Friday's session at EUR 83.80, down 2.6%, a move that looks less like panic and more like consolidation after investors had already priced in encouraging oncology news. The stock is now trading roughly a fifth below its 52-week high of EUR 105.80, set in January, and sits just under both its 50-day moving average of EUR 84.37 and its 200-day average of EUR 84.21 — a sign the shares have drifted back to their medium-term equilibrium.

What failed to lift the stock was a fresh regulatory green light. Health Canada on Thursday approved an XFG-adapted version of the Covid-19 vaccine Comirnaty from Pfizer and BioNTech for people aged six months and older, a decision that mirrors moves by other regulators responding to the shifting virus landscape. For shareholders, though, the approval offers no new growth story. BioNTech's coronavirus business has been contracting for months, and one more market authorization does little to change that trajectory.

A Vaccine Franchise in Retreat

The latest quarterly figures lay bare the scale of that decline. In the second quarter of 2026, BioNTech booked revenue of EUR 105.6 million, a fraction of the EUR 260.8 million posted a year earlier. The net loss came in at EUR 820.8 million, or EUR 562.3 million on an adjusted basis. Management responded by cutting its full-year revenue guidance to a range of EUR 1.6 billion to EUR 1.9 billion, down from an earlier target of EUR 2.0 billion to EUR 2.3 billion.

The erosion of Comirnaty revenue — once the cash engine that bankrolled expensive research programs — is now outpacing the company's ability to bring new blockbusters to market. That mismatch sits at the heart of BioNTech's transition from pandemic darling to diversified cancer specialist, and it is testing investors' patience.

Oncology Delivers a Genuine Bright Spot

Against that backdrop, the pipeline has produced a genuine bright spot. BioNTech and partner OncoC4 reported updated data for Gotistobart (BNT316/ONC-392) showing a median overall survival of 18.5 months in previously treated squamous NSCLC in the Phase 3 PRESERVE-003 trial — nearly double the 10.0 months achieved with docetaxel. Those results had earlier galvanized the shares and demonstrated that BioNTech is more than a pure vaccine maker.

Yet clinical wins of this kind can only partially mask the structural drag in the business model. The path to approval for proprietary cancer drugs remains rocky, as a setback roughly two weeks ago made clear: BioNTech halted a mid-stage study of Autogene Cevumeran in colorectal cancer after an independent committee concluded the treatment was unlikely to deliver a survival benefit. The company, citing Reuters, stressed that the decision does not affect a separate pancreatic cancer trial being run with Genentech. Even so, the discontinuation leaves a mark on confidence in the individualized mRNA program iNeST.

Analysts Turn Cautious

That combination of factors prompted BMO Capital Markets to downgrade the stock on September 8 from Outperform to Market Perform, with a lowered price target of USD 105. The firm pointed not only to the unexpectedly sharp erosion of Comirnaty but also to diminished expectations for iNeST. It further noted that solid risk-reduction data for the hoped-for asset Pumitamig will not be available until 2028 — a gap to commercial maturity that, from this vantage point, looks very wide indeed.

A Balance Sheet Built for the Long Haul

BioNTech's finances, at least, provide ample room to keep funding research. At the end of the second quarter of 2026, the company held cash and marketable securities of EUR 16.6 billion. In June, the supervisory board also approved a new buyback program for American Depositary Shares worth up to USD 1.0 billion, financed from existing cash and running through May 2027.

Even with that cushion, shareholders should brace for a multi-year slog. Near-term questions outweigh answers: data like Gotistobart's show real scientific potential, but until partial clinical successes convert into commercial revenue, the drag from vanishing legacy sales is likely to dominate. For now, the stock remains one for investors with a long horizon — and with a high tolerance for pipeline setbacks that can dent sentiment at any moment.